Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mus musculus

ABSTRACT: A Cross-Species Approach Identifies MELK as a Potential Therapeutic Target in Prostate Cancer

PROVIDER: PRJNA371484 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5232190.fastq.gz	Fastqsanger.gz
	SRR5232200.fastq.gz	Fastqsanger.gz
	SRR5232210.fastq.gz	Fastqsanger.gz
	SRR5232220.fastq.gz	Fastqsanger.gz
	SRR5232230.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 917

Similar Datasets

Cross-Species Approach Identifies MELK as a Potential Therapeutic Target in Prostate Cancer

Project description:Cross-Species Approach Identifies MELK as a Potential Therapeutic Target in Prostate Cancer

| PRJNA394748 | ENA

Identification of MELK-regulated genes in prostate cancer cells using next-generation sequencing

Project description:A cross-species analysis identified MELK as a potential therapeutic target in prostate cancer. To further elucidate the functional role of MELK in prostate cancer cells, we aimed to identify MELK-regulated genes. C4-2b cells were either treated with a small-molecule MELK inhibitor (OTSSP167), or transfected with siRNAs targeting MELK. Differentially expressed genes were identified using next-generation sequencing. Our results demonstrate that MELK promotes the expression of genes associated with tumour progression in prostate cancer cells.

2018-02-05 | GSE94570 | GEO

A Cross-Species Approach Identifies MELK as a Potential Therapeutic Target in Prostate Cancer

Project description:Genetically engineered mouse models of cancer represent valuable biological tools that can be used to filter genome-wide expression datasets generated from human prostate tumours, and identify gene expression alterations that are functionally important to cancer development and progression. In this study, we have generated RNASeq data from tumours arising in two established mouse models of prostate cancer, PB-Cre/PtenloxP/loxP and p53loxP/loxPRbloxP/loxP, and integrated this with published human prostate cancer expression data to pinpoint cancer-associated gene expression changes that are conserved between the two species. In order to identify potential therapeutic targets, we then filtered this information for genes that are either known or predicted to be druggable. Using this approach, we identified the serine/threonine kinase MELK as a potential therapeutic target in prostate cancer. MELK was overexpressed in both human and murine prostate cancers, and high expression of MELK was associated with biochemical recurrence in prostate cancer patients.

2018-02-05 | GSE94574 | GEO

MELK and UBE2C gene knockdown in prostate cancer cell line PC3

Project description:In order to address the putative role of MELK and UBE2C in prostate cancer development and progression, we performed functional analysis upon siRNA-based knockdown, and searched for downstream genes and processes by microarray experiments. RNAi-based inhibition of MELK and UBE2C was efficient in PC3 prostate cancer cells and decreased transcriptional level down to about 30% remaining expression level.

2012-10-19 | GSE32873 | GEO

Inhibition of Androgen Receptor and β-catenin activity in prostate cancer

Project description:Androgen receptor (AR) is the major therapeutic target in aggressive prostate cancer. However, targeting AR alone can result in drug resistance and disease recurrence. Therefore, simultaneous targeting of multiple pathways could in principle be an effective new approach to treating prostate cancer. Here we provide proof-of-concept that a small molecule inhibitor of nuclear β-catenin activity (called C3) can inhibit both the AR and β-catenin signaling pathways that are often misregulated in prostate cancer. Treatment with C3 ablated prostate cancer cell growth by disruption of both β-catenin/TCF and β-catenin/AR protein interaction, reflecting the fact that TCF and AR have overlapping binding sites on β-catenin. Given that AR interacts with, and is transcriptionally regulated by β-catenin, C3 treatment also resulted in decreased occupancy of β-catenin on the AR promoter and diminished AR and AR/β-catenin target gene expression. Interestingly, C3 treatment resulted in decreased AR binding to target genes accompanied by decreased recruitment of an AR and β-catenin cofactor, CARM1, providing new insight into the unrecognized function of β-catenin in prostate cancer. Importantly, C3 inhibited tumor growth in an in vivo xenograft model, and blocked renewal of bicalutamide-resistant sphere forming cells, indicating the therapeutic potential of this approach. Compare and contrast the expression profile of prostate cancer cells treated with a Wnt inhibitor (C3) with respect to β-catenin and AR knockdown (all samples in duplicates).

2014-01-23 | E-GEOD-49295 | biostudies-arrayexpress

Homo sapiens

Project description:Identification of DEK as a potential therapeutic target for Neuroendocrine prostate cancer

| PRJNA260520 | ENA

MELK and UBE2C gene knockdown in prostate cancer cell line PC3

2012-10-19 | E-GEOD-32873 | biostudies-arrayexpress

Canine osteosarcoma tissues vs. normal bone

Project description:Leveraging the conserved cancer genomes across mammals has the potential to transform driver gene discovery in orphan cancers. Here, we combine cross-species genomics with validation across human-dog-mouse systems to uncover a new osteosarcoma driver genes. This widely applicable cross-species approach serves as a platform to expedite search of cancer drivers in rare human malignancies offering new targets for cancer therapy.

2021-03-08 | GSE111637 | GEO

Canine pimary osteosarcoma tissues vs. matched lung metastases

Project description:Osteosarcomas (OS) have highly chaotic genomes, yet their cancer drivers are poorly defined. Given that cancer genes are conserved among mammals, cross-species genomics of naturally arising cancers opens a powerful approach to identifying oncogenic drivers to broaden the therapeutic opportunities for aggressive cancers. Here, we utilized a dog-to-human cross-species genomics combined with gain- and loss-of-function analysis to uncover novel OS driver genes.

2021-08-03 | GSE118130 | GEO

The role of MELK in melanoma progression

Project description:Survival kinase MELK has been shown to be important for proliferation of several tumors such as brain, breast or prostate. MELK expression is elevated in cutaneous melanoma, therefore, we analyzed the role of MELK in melanoma. Inhibition of MELK in melanoma cell lines resulted in decreased proliferation, increased cell death and decreased invasion. MELK expression is regulated through MAP kinase pathway and inhibition of MAPK pathway leads to diminished MELK expression. Finally, inhibition of MELK reduces tumor size in nude mice.

2020-12-30 | GSE83907 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data